Európai Unió - lett - EMA (European Medicines Agency)

pfizer europe ma eeig  - palbociklibs - krūts audzējs - antineoplastiski līdzekļi - ibrance ir indicēts, lai ārstētu hormonu receptoru (ap) pozitīvs, cilvēka epidermas augšanas faktora receptora 2 (her2) negatīvs vietas papildu vai metastātisku krūts vēzi:kombinācijā ar aromatāzes inhibitoru;kopā ar fulvestrants sievietes, kas ir saņemti pirms endokrīnās terapijas. pre - vai perimenopausal sievietēm, endokrīnās terapijas būtu jāapvieno ar luteinizējošais hormona atbrīvojošo hormonu (lhrh) agonistu.

Európai Unió - lett - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoklakss - leikēmija, limfocītu, hroniska, b-šūna - antineoplastiski līdzekļi - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Lettország - lett - Zāļu valsts aģentūra

uab johnson & johnson, lithuania - ethinylestradiolum, norgestimatum - tabletes - 250/35 μg

Lettország - lett - Zāļu valsts aģentūra

gedeon richter plc., hungary - ethinylestradiolum, chlormadinoni acetas - apvalkotā tablete - 0,03 mg/2 mg

Lettország - lett - Zāļu valsts aģentūra

gedeon richter plc., hungary - levonorgestrelum, ethinylestradiolum - apvalkotā tablete - 150 μg/30 μg

Lettország - lett - Zāļu valsts aģentūra

exeltis baltics uab, lithuania - chlormadinoni acetas, ethinylestradiolum - apvalkotā tablete - 2 mg/0,03 mg

Európai Unió - lett - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - karcinoma, nesīkšūnu plaušas - antineoplastiski līdzekļi - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

Lettország - lett - Zāļu valsts aģentūra

gedeon richter plc., hungary - chlormadinoni acetas, ethinylestradiolum - apvalkotā tablete - 2 mg/0,03 mg

Lettország - lett - Zāļu valsts aģentūra

gedeon richter plc., hungary - gestodenum, ethinylestradiolum - apvalkotā tablete - 75 μg/20 μg

Lettország - lett - Zāļu valsts aģentūra

gedeon richter plc., hungary - gestodenum, ethinylestradiolum - apvalkotā tablete - 75 μg/30 μg